Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) Overview 9 Therapeutics Development 10 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Stage of Development 10 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Therapy Area 11 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Indication 12 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Companies 16 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Universities/Institutes 21 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30 Array BioPharma Inc. 30 Astellas Pharma Inc. 31 AstraZeneca Plc 32 Creabilis SA 33 Daiichi Sankyo Company, Limited 34 Dompe Farmaceutici S.p.A. 35 Genzyme Corporation 36 Glenmark Pharmaceuticals Ltd. 37 Ignyta, Inc. 38 Loxo Oncology, Inc. 39 Mimetogen Pharmaceuticals Inc. 40 Nerviano Medical Sciences S.r.l. 41 Purdue Pharma L.P. 42 SOM Innovation Biotech SL 43 Tiziana Life Sciences Plc 44 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles 45 AR-523 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 AR-786 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 ARRY-954 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ASP-7962 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AZ-64 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AZD-7451 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 CRB-0089 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 CT-327 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 CT-340 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 entrectinib - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 GBR-900 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 GZ-389988 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 lestaurtinib - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 LOXO-101 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 milciclib - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 NMSP-626 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 PLX-7486 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Synthetic Peptide for Neurology - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 tavilermide hydrochloride - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 VM-902A - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Projects 81 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products 86 High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Featured News & Press Releases 89 Jul 13, 2016: Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 89 Jun 15, 2016: Loxo Oncology Accepts Invitation to Present LOXO-101 to the FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee 89 Apr 19, 2016: Loxo Oncology Announces First Pediatric Response to LOXO-101 90 Apr 17, 2016: Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update 91 Apr 17, 2016: Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting 94 Apr 11, 2016: Loxo Oncology to Present Updated LOXO-101 Phase 1 Data at the 2016 AACR Annual Meeting 96 Apr 07, 2016: Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting 97 Jan 15, 2016: Loxo Oncology Announces EMA Orphan Drug Designation Granted to LOXO-101 for Treatment of Soft Tissue Sarcoma 98 Dec 22, 2015: Loxo Oncology Announces First Patient Enrolled in Phase 1 Trial of LOXO-101 in Pediatric Cancer Patients 98 Dec 09, 2015: Ignyta Announces Initiation of STARTRK "Next Generation" Phase 1/1b Pediatric Clinical Trial of Entrectinib 99 Dec 08, 2015: Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma 100 Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency 100 Nov 30, 2015: Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program 101 Nov 08, 2015: Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial 102 Oct 28, 2015: Loxo Oncology Announces Selection of LOXO-101 for NCI-MATCH Precision Medicine Clinical Trial 103 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 105 Disclaimer 106

List of Tables Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Development by Companies, H2 2016 (Contd..2) 19 Products under Development by Companies, H2 2016 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pipeline by Array BioPharma Inc., H2 2016 30 Pipeline by Astellas Pharma Inc., H2 2016 31 Pipeline by AstraZeneca Plc, H2 2016 32 Pipeline by Creabilis SA, H2 2016 33 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34 Pipeline by Dompe Farmaceutici S.p.A., H2 2016 35 Pipeline by Genzyme Corporation, H2 2016 36 Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 37 Pipeline by Ignyta, Inc., H2 2016 38 Pipeline by Loxo Oncology, Inc., H2 2016 39 Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016 40 Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 41 Pipeline by Purdue Pharma L.P., H2 2016 42 Pipeline by SOM Innovation Biotech SL, H2 2016 43 Pipeline by Tiziana Life Sciences Plc, H2 2016 44 Dormant Projects, H2 2016 81 Dormant Projects (Contd..1), H2 2016 82 Dormant Projects (Contd..2), H2 2016 83 Dormant Projects (Contd..3), H2 2016 84 Dormant Projects (Contd..4), H2 2016 85 Discontinued Products, H2 2016 86 Discontinued Products (Contd..1), H2 2016 87 Discontinued Products (Contd..2), H2 2016 88 List of Figures Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Top 10 Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Mechanism of Actions, H2 2016 24 Number of Products by Stage and Mechanism of Actions, H2 2016 24 Number of Products by Routes of Administration, H2 2016 26 Number of Products by Stage and Routes of Administration, H2 2016 26 Number of Products by Molecule Types, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 28

Array BioPharma Inc. Astellas Pharma Inc. AstraZeneca Plc Creabilis SA Daiichi Sankyo Company, Limited Dompe Farmaceutici S.p.A. Genzyme Corporation Glenmark Pharmaceuticals Ltd. Ignyta, Inc. Loxo Oncology, Inc. Mimetogen Pharmaceuticals Inc. Nerviano Medical Sciences S.r.l. Purdue Pharma L.P. SOM Innovation Biotech SL Tiziana Life Sciences Plc